Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income: 2017-2023

Historic Non Operating Income for Denali Therapeutics (DNLI) over the last 7 years, with Dec 2023 value amounting to $13.1 million.

  • Denali Therapeutics' Non Operating Income rose 97.13% to $13.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $51.5 million, marking a year-over-year increase of 248.62%. This contributed to the annual value of $51.5 million for FY2023, which is 248.62% up from last year.
  • According to the latest figures from Q4 2023, Denali Therapeutics' Non Operating Income is $13.1 million, which was down 9.09% from $14.4 million recorded in Q3 2023.
  • In the past 5 years, Denali Therapeutics' Non Operating Income registered a high of $14.4 million during Q3 2023, and its lowest value of $1.0 million during Q3 2021.
  • For the 3-year period, Denali Therapeutics' Non Operating Income averaged around $5.9 million, with its median value being $3.4 million (2022).
  • Its Non Operating Income has fluctuated over the past 5 years, first slumped by 61.58% in 2021, then surged by 763.38% in 2023.
  • Over the past 5 years, Denali Therapeutics' Non Operating Income (Quarterly) stood at $3.8 million in 2019, then tumbled by 57.20% to $1.6 million in 2020, then dropped by 21.17% to $1.3 million in 2021, then surged by 418.29% to $6.7 million in 2022, then skyrocketed by 97.13% to $13.1 million in 2023.
  • Its Non Operating Income stands at $13.1 million for Q4 2023, versus $14.4 million for Q3 2023 and $12.9 million for Q2 2023.